NCT05460455View on ClinicalTrials.gov

A Study to Evaluate Multi-dose of HB0034 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 13, 2022

Primary Completion Date

June 9, 2023

Study Completion Date

December 8, 2023

Conditions
Healthy
Interventions
DRUG

Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo

HB0034 and Placebo

Trial Locations (1)

Unknown

New zealand Clinical Research, Auckland

All Listed Sponsors
lead

Shanghai Huaota Biopharmaceutical Co., Ltd.

INDUSTRY